Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial

Area of Science:

• Pharmacology
• Clinical Trials
• Addiction Medicine

Background:

• New smoking cessation aids are needed.
• Cytisinicline, a partial agonist of nicotinic acetylcholine receptors, has shown promise in prior trials.
• Further evidence is required to confirm its efficacy and tolerability.

Purpose of the Study:

• To replicate previous findings on cytisinicline's efficacy and tolerability for smoking cessation.
• To assess cytisinicline's impact on nicotine craving as a potential mechanism of action.

Main Methods:

• A 3-group, double-blind, placebo-controlled Phase 3 randomized clinical trial (ORCA-3) was conducted.
• Adult smokers received 6 or 12 weeks of cytisinicline or placebo, with behavioral support.
• Primary outcomes included biochemically verified continuous smoking abstinence.

Main Results:

• Both 6- and 12-week cytisinicline regimens significantly increased smoking abstinence rates compared to placebo.
• Cytisinicline treatment led to a greater reduction in nicotine craving.
• The medication was well-tolerated, with no serious adverse events related to treatment.

Conclusions:

• The ORCA-3 trial confirms cytisinicline's efficacy and tolerability for smoking cessation.
• Benefits were observed through 24 weeks of follow-up.
• Cytisinicline effectively mitigates nicotine craving, supporting its role as a smoking cessation aid.